BiotechTube

Enfortumab Vedotin + Pembrolizumab

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bladder Squamous Cell Carcinoma

Conditions

Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Neoplasm, Malignant Ureter Neoplasm, Malignant Urethral Neoplasm, Metastatic Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Unresectable Bladder Carcinoma, Urachal Adenocarcinoma, Bladder Adenocarcinoma

Trial Timeline

Sep 26, 2023 → Dec 16, 2027

NCT ID
NCT05756569

About Enfortumab Vedotin + Pembrolizumab

Enfortumab Vedotin + Pembrolizumab is a phase 2 stage product being developed by Astellas Pharma for Bladder Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05756569. Target conditions include Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Neoplasm.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (7)

NCT IDPhaseStatus
NCT07475806Phase 2Recruiting
NCT06906822Phase 2Recruiting
NCT06809140Phase 2Recruiting
NCT06470282Phase 1/2Recruiting
NCT05756569Phase 2Recruiting
NCT05239624Phase 2Recruiting
NCT04225117Phase 2Active

Competing Products

20 competing products in Bladder Squamous Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
51
EG-70 (phase 1) + EG-70 (phase 2)enGenePhase 1/2
33
mirabegron + solifenacinAstellas PharmaApproved
85
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Enfortumab vedotinAstellas PharmaPhase 1
33
Mirabegron + PlaceboAstellas PharmaApproved
85
SolifenacinAstellas PharmaApproved
85
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
77
solifenacin succinateAstellas PharmaPhase 3
77
SolifenacinAstellas PharmaPre-clinical
23
BetanisAstellas PharmaPre-clinical
23
SolifenacinAstellas PharmaApproved
85
SolifenacinAstellas PharmaPhase 2
52
Mirabegron + Tolterodine ERAstellas PharmaApproved
85
mirabegron + solifenacin + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine + propiverineAstellas PharmaPre-clinical
23
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
52
MK-3475 + ASG-22CEAstellas PharmaPhase 2
52
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
85
warfarin + YM178Astellas PharmaPhase 1
33
Pembrolizumab + Enfortumab vedotin (EV) + Gemcitabine + CisplatinAstellas PharmaPhase 3
77

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85